Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Sanofi Pasteur, a Sanofi Company
Data will be recorded prospectively during the safety follow-up for pregnant women until delivery (or pregnancy outcome, whichever is later), and for infants of pregnant women for 1 year after birth.
Age
0–64
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Pregnant women:
Laboratory or medical professional confirmation of pregnancy
Exposure to either Flublok Quadrivalent influenza vaccine or standard-dose quadrivalent inactivated influenza vaccine (SD-IIV4) in the VAP00003 Study during pregnancy or within 28 days preceding conception
Offspring:
You may not be if
Documented receipt of any other influenza vaccine at any other time during the pregnancy
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Clareo Health | Surveillance Study to Assess the Safety of Flublok Quadrivalent (Influenza Vaccine) in Pregnant Women and Their Offspring
